{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IL-12+DNA&page=2", "query": { "intervention": "IL-12 DNA", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IL-12+DNA&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-28T01:59:19.415Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04357821", "title": "Combinatorial Therapy to Induce an HIV Remission", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV/AIDS" ], "interventions": [ { "name": "Combination Intervention", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "67 Years", "sex": "ALL", "summary": "18 Years to 67 Years" }, "enrollment_count": 11, "start_date": "2020-08-01", "completion_date": "2025-06-12", "has_results": true, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-09-28T01:59:19.415Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04357821" }, { "nct_id": "NCT05781542", "title": "Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "sD-NP-GT8 DNA", "type": "BIOLOGICAL" }, { "name": "IL-12 DNA", "type": "BIOLOGICAL" }, { "name": "Trimer 4571", "type": "BIOLOGICAL" }, { "name": "3M-052-AF", "type": "BIOLOGICAL" }, { "name": "Alum", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 46, "start_date": "2023-04-10", "completion_date": "2025-04-14", "has_results": true, "last_update_posted_date": "2025-11-14", "last_synced_at": "2026-09-28T01:59:19.415Z", "location_count": 4, "location_summary": "Birmingham, Alabama • San Francisco, California • Boston, Massachusetts", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05781542" }, { "nct_id": "NCT00775424", "title": "PENNVAX-B With or Without IL-12 or IL-15 as a DNA Vaccine for HIV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "PENNVAX-B", "type": "BIOLOGICAL" }, { "name": "GENEVAX IL-12-4532", "type": "BIOLOGICAL" }, { "name": "PLACEBO", "type": "BIOLOGICAL" }, { "name": "IL-15 adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 38, "start_date": "2008-09", "completion_date": "2010-06", "has_results": false, "last_update_posted_date": "2016-08-25", "last_synced_at": "2026-09-28T01:59:19.415Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00775424" }, { "nct_id": "NCT00111605", "title": "Study of an HIV Preventive Vaccine Given With or Without an Adjuvant in HIV Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "HIV-1 gag DNA", "type": "BIOLOGICAL" }, { "name": "HIV-1 gag DNA plus IL-12 DNA adjuvant", "type": "BIOLOGICAL" }, { "name": "CTL MEP/RC529-SE/GM-CSF (CTL MEP vaccine)", "type": "BIOLOGICAL" }, { "name": "Sodium chloride injection (0.9%)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 144, "start_date": null, "completion_date": "2008-05", "has_results": false, "last_update_posted_date": "2021-10-14", "last_synced_at": "2026-09-28T01:59:19.415Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Nashville, Tennessee", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00111605" }, { "nct_id": "NCT03606213", "title": "Therapeutic Vaccination in Treated HIV Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "PENNVAX-GP", "type": "BIOLOGICAL" }, { "name": "INO-6145", "type": "BIOLOGICAL" }, { "name": "INO-9012", "type": "BIOLOGICAL" }, { "name": "CELLECTRA® 2000", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE" ], "sponsor": "Steven Deeks", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 56, "start_date": "2018-08-01", "completion_date": "2021-05-17", "has_results": true, "last_update_posted_date": "2023-05-31", "last_synced_at": "2026-09-28T01:59:19.415Z", "location_count": 2, "location_summary": "Los Angeles, California • San Francisco, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03606213" }, { "nct_id": "NCT00991354", "title": "Safety of and Immune Response to the PENNVAX-B DNA Vaccine With and Without IL-12 in HIV-uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "PENNVAX-B", "type": "BIOLOGICAL" }, { "name": "IL-12 DNA plasmids", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 48, "start_date": "2009-11", "completion_date": "2011-03", "has_results": false, "last_update_posted_date": "2021-10-14", "last_synced_at": "2026-09-28T01:59:19.415Z", "location_count": 3, "location_summary": "Rochester, New York • Philadelphia, Pennsylvania • Nashville, Tennessee", "locations": [ { "city": "Rochester", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00991354" }, { "nct_id": "NCT01266616", "title": "Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Profectus HIV MAG pDNA vaccine", "type": "BIOLOGICAL" }, { "name": "IL-12", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 62, "start_date": "2011-03", "completion_date": "2013-04", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-09-28T01:59:19.415Z", "location_count": 13, "location_summary": "Los Angeles, California • Palo Alto, California • San Francisco, California + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01266616" }, { "nct_id": "NCT03439085", "title": "DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Human Papillomavirus-16 Positive", "Human Papillomavirus-18 Positive", "Metastatic Malignant Neoplasm", "Recurrent Anal Canal Carcinoma", "Recurrent Cervical Carcinoma", "Recurrent Malignant Neoplasm", "Recurrent Penile Carcinoma", "Recurrent Vaginal Carcinoma", "Recurrent Vulvar Carcinoma", "Refractory Malignant Neoplasm", "Stage IV Anal Cancer AJCC v8", "Stage IV Cervical Cancer AJCC v8", "Stage IV Penile Cancer AJCC v8", "Stage IV Vaginal Cancer AJCC v8", "Stage IV Vulvar Cancer AJCC v8", "Stage IVA Cervical Cancer AJCC v8", "Stage IVA Vaginal Cancer AJCC v8", "Stage IVA Vulvar Cancer AJCC v8", "Stage IVB Cervical Cancer AJCC v8", "Stage IVB Vaginal Cancer AJCC v8", "Stage IVB Vulvar Cancer AJCC v8" ], "interventions": [ { "name": "DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457", "type": "BIOLOGICAL" }, { "name": "Durvalumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2018-11-14", "completion_date": "2022-09-20", "has_results": true, "last_update_posted_date": "2024-07-09", "last_synced_at": "2026-09-28T01:59:19.415Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03439085" }, { "nct_id": "NCT04015700", "title": "Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics", "type": "BIOLOGICAL" }, { "name": "CELLECTRA®2000 EP Device supplied by Geneos Therapeutics", "type": "DEVICE" }, { "name": "Plasmid encoded IL-12", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE", "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2020-07-14", "completion_date": "2027-09-03", "has_results": true, "last_update_posted_date": "2026-05-07", "last_synced_at": "2026-09-28T01:59:19.415Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04015700" }, { "nct_id": "NCT00115960", "title": "Safety of and Immune Response to an HIV Preventive Vaccine (HIV-1 Gag DNA Alone or With IL-15 DNA) Given With or Without 2 Different Booster Vaccinations in HIV Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "HIV-1 gag DNA", "type": "BIOLOGICAL" }, { "name": "IL-15 DNA adjuvant", "type": "BIOLOGICAL" }, { "name": "IL-12 DNA adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 120, "start_date": null, "completion_date": "2008-07", "has_results": false, "last_update_posted_date": "2021-10-14", "last_synced_at": "2026-09-28T01:59:19.415Z", "location_count": 6, "location_summary": "Boston, Massachusetts • New York, New York • Rochester, New York + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Rochester", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00115960" } ] }